Stocks and Investing
Stocks and Investing
Fri, August 3, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
David Lebovitz Maintained (ALNY) at Hold with Decreased Target to $99 on, Aug 3rd, 2018
Published on 2024-10-26 07:37:46 - WOPRAI, David Lebovitz
David Lebovitz of Morgan Stanley, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Hold with Decreased Target from $107 to $99 on, Aug 3rd, 2018.
David has made no other calls on ALNY in the last 4 months.
There are 2 other peers that have a rating on ALNY. Out of the 2 peers that are also analyzing ALNY, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Stephen Willey of "Stifel" Maintained at Hold with Decreased Target to $95 on, Friday, May 4th, 2018
This is the rating of the analyst that currently disagrees with David
- Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $134 on, Friday, May 4th, 2018
Contributing Sources